Showing results (151-160 of 178) with videos related to
Sort By:
Pageof 18
Clinical Lung Cancer|January 19, 2025
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket TrialJonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, et al.The Lancet. Oncology|July 15, 2019
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trialRoy S Herbst, Hendrik-Tobias Arkenau, Rafael Santana-Davila, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyMark N Stein, Armelle Vinceneux, Debbie Robbrecht, et al.The Oncologist|April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspectiveMerel J J Lucassen, Pedro Bergmann, Olga Husson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung CancerMehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid TumorsIgnacio Melero, Josep Tabernero, Neeltje Steeghs, et al.Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.The Lancet. Oncology|June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialScott J Antonia, José A López-Martin, Johanna Bendell, et al.Pageof 18